NEWS

MRVL Pet Pharmaceuticals™ Executes Agreement with Altran for FDA Clinical Trials on Canine and Feline Cancer and Arthritis Treatment Products

Renowned Veterinary Expert Dr. Albert Ahn Appointed Chief Researcher of Clinical Trial.

Deborah Cenci, A.V.P of Regulatory Affairs, Quality and Compliance at Altran, Appointed Clinical Trial Manager.

Toronto, ON and Vancouver, BC – March 15, 2021 – MRVL Pet Pharmaceuticals™ Corp. (the “Company” or “MRVL”), a life sciences and technology company focused on the animal health sector, today announced it has entered into an agreement with the Life Sciences division of Altran, a Capgemini company, to provide advisory services on their U.S. FDA clinical trial process for canine and feline cancer and arthritis products. The clinical trial launched on January 27, 2021 and is expected to consist of three phases and run until December 30, 2022.

Altran, the world leader in a global engineering and R&D services, helps its clients meet their innovation challenges and is part of Capgemini’s global network of over 270,000 employees in over nearly 50 countries. Altran’s Life Sciences Division aims to bring better drugs and medical products to market faster with less risk – the perfect balance MRVL requires to address the rising pet health crisis.

“Currently in the United States, 12 million dogs and cats are diagnosed with cancer each year,” said MRVL CEO Dr. Joel Beth Navratik. “Additionally, 3 in 4 dogs over the age of 7 and over 90% of geriatric cats suffer from arthritis. The current veterinary market only offers four oncology products, and all other options are off-label human oncology products that are toxic such as chemotherapy – there is a global demand for our products.”

MRVL’s products feature the proprietary formula, Blue Scorpion Peptide CTX™, a combination of 36 amino acids extracted and purified from natural blue scorpion venom. Among countless other pet health benefits, scorpion venom’s amino acids form peptides that can potentially destroy cancer cells and diminish arthritis pain leading to an improved quality of life for companion animals. Upon U.S. FDA approval, MRVL’s products will enter the growing $15.3 billion global companion healthcare market, expected to reach $20.7 billion by 2025.

The three-phase trials will be conducted by Chief Researcher Dr. Albert Ahn, a renowned expert with over 25 years of knowledge and practice in veterinary medicine. Dr. Ahn has a high success rate for FDA approvals, and has run clinical trials for many blockbuster drugs including Frontline, Heartgard and Vectra 3D.

Joining Dr. Ahn is Deborah Cenci, A.V.P of Regulatory Affairs, Quality and Compliance at Altran. Ms. Cenci will assume the role of Clinical Trial Manager, also bringing over 25 years of experience with regulatory and compliance in the pharmaceutical industry. She has provided international R&D and regulatory strategies for over 320 Rx Drugs.

“Dr. Ahn and I are excited about this groundbreaking and innovative line of global non-invasive therapeutic solutions for companion pets. After 30 years of combined life sciences experience and over 360 Rx Drug approvals and launches, we are extremely confident that MRVL will not only obtain regulatory approval but will also become a global leader in the industry. We feel that MRVL will fulfill an important unmet need in veterinary oncology and arthritis for companion pets. With an initial focus on mass cell tumor for canines and lymphoma cancers for feline pets,” explained Cenci.

“Dr. Ahn and Ms. Cenci’s competencies and experience, matched with Altran’s commitment to MRVL, will prove to be huge assets as we embark through this significant milestone. These trials are the first step to entering the market with products that are non-toxic, safe, and effective to treat our four-legged companions,” stated Dr. Navratik.

About MRVL PET Pharmaceuticals™ Corp.

MRVL PET Pharmaceuticals™ Corp. is a life sciences and technology company focused on the animal health sector with a primary mission of developing and marketing its companion animal products to the retail and veterinary markets. MRVL is developing products targeting canine and feline cancer and arthritis for CVM/FDA approval as well as launching a nutraceutical formulation for pet immune and joint support.

MRVL has entered into an agreement to acquire MRVL Island Ventures Limited (“MRVL Island”), which is expected to close imminently. MRVL Island is the holder of an exclusive license to manufacture, use, and sell its proprietary Blue Scorpion venom and Blue Scorpion Peptide CTX throughout North America, Europe and the United Kingdom.

MRVL PET PHARMACEUTICALS CORP.

Dr. Joel Beth Navratik,
Chief Executive Officer
Email: [email protected]

Cautionary Statements

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward-looking statements in this release include but are not limited to the following: (i) the Company’s expectation that the three phases of the clinical trials will be completed by December 30, 2022; (ii) there being global demand for the Company’s products; (iii) the Company becoming a global leader in its industry; and (iv) the ability of the Company’s products to destroy cancer cells and diminish arthritis pain leading to an improved quality of life for companion animals. Forward-looking statements in this release are based on assumptions which included but are not limited to the following: (i) the management of the Company proceeding with the clinical trial on the timelines indicated in the press release; (ii) the success of the Company’s clinical trials in establishing its products can treat cancer and arthritis in companion pets, thereby driving global demand for the Company’s products; (iii) the clinical trials establishing that the Company’s products are materially superior to its competitors’ products; and (iv) that the Company’s initial in-house research on its products will be validated by the clinical trials and establish the Company’s products can treat arthritis and cancer in pets. While MRVL considers these assumptions to be reasonable, based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including without limitation, risks associated with delays in completing the clinical trials, the clinical trials establishing that the Company’s products are not effective to treat cancer or arthritis in pets or that they do treat cancer and arthritis but less effectively than indicative by the Company’s in-house research, that competitors will develop products that are superior in quality to the Company’s and thereby reduce the probability the Company becomes a global leader in pet pharmaceuticals, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, and the inability to access sufficient capital on favourable terms or at all.